# Alvotech (ALVO) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $5.32, market value $1.9 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Alvotech reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **PEG: 0.21**. A PEG of 0.21 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 3.9×**. Each dollar of revenue is priced at 3.9×.
- **EV / EBITDA: 19.7×**. Enterprise value is 19.7× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: -17.6%** (5-yr avg -11.7%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 60.4%**. Alvotech keeps 60.4% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 9.7%**. 9.7% of revenue is left after running the business.
- **Net margin: 4.8%**. 4.8% of each dollar of sales reaches the bottom line.
- **Return on equity: -9.8%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 5.9%**. Return on all capital, debt included, is 5.9%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -12.1%**. Each dollar of assets produces -12.1% of profit.

## Growth
- **Revenue growth (1 yr): 19.7%** (3-yr 91.9%/yr, 5-yr 54.5%/yr). Revenue grew 19.7% over the last year, against 54.5% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 111.5%**. Earnings per share rose 111.5%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Net debt / EBITDA: 7.2×**. It would take 7.2 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Interest coverage: 0.3×**. Operating profit covers interest only 0.3×: fragile.
- **Altman Z-score: 0.94**. A Z-score of 0.94 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Alvotech does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (5 analysts). 5 analysts cover Alvotech; the consensus is buy, with an average price target of $6.00 (+13% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -33.8%** (YTD 3.7%, 3-mo 50.3%). The shares are down 33.8% over twelve months including dividends.
- **From 52-week high: -42.5%** (81.0% above the low). Trading 42% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 72**. An RSI of 72 is in overbought territory; short-term pullbacks are common from here.
- **Beta (1 yr): 0.59** (volatility 77%). Beta of 0.59 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ALVO · Page: https://foliofundamentals.com/stocks/alvo

Not investment advice.